OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Publication Date
Release Date
2022
(3)
2025
(1)
2024
(1)
2023
(1)
2021
(1)
2020
(1)
2019
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Assessment of genetic diversity and genetic structure of wild rice populations in Myanmar.
Not available
S-EPMC6776141
|
biostudies-literature
Cite
Transcutaneous bilirubin-based screening reduces the need for blood exchange transfusion in Myanmar newborns: A single-center, retrospective study.
Not available
S-EPMC9485474
|
biostudies-literature
Cite
Assessing risk factors and impact of cyberbullying victimization among university students in Myanmar: A cross-sectional study.
Not available
S-EPMC6975531
|
biostudies-literature
Cite
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Not available
S-EPMC10666914
|
biostudies-literature
Cite
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
Not available
S-EPMC11952008
|
biostudies-literature
Cite
An open dataset of
Plasmodium vivax
genome variation in 1,895 worldwide samples.
Not available
S-EPMC9127374
|
biostudies-literature
Cite
Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study.
Not available
S-EPMC8677532
|
biostudies-literature
Cite
Electrodiagnostic subtyping in Guillain-Barre syndrome patients in the International Guillain-Barre Outcome Study.
Not available
S-EPMC11295174
|
biostudies-literature
Cite
International Validation of the Erasmus Guillain-Barre Syndrome Respiratory Insufficiency Score.
Not available
S-EPMC9306880
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets